Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
shop dildos - is great for every girl.
Popular Articles

Recession And Budget Cuts Hit Children Especially Hard
As the recession forces more hospitals and doctors to pare costs and services, children are being especially hard hit.
drugs without prescription
To Maintain Normal Daily Function, Those With Insomnia Need Increased Brain Activation
According to a research abstract presented at SLEEP 2009, the 23rd Annual Meeting of the Associated Professional Sleep Societies, patients suffering from chronic primary insomnia (PIs) have higher levels of brain activation compared to normal sleepers during a working memory test.
News of the day
MGH Study Identifies First Molecular Steps To Childhood Leukemia
A Massachusetts General Hospital (MGH)-based research team has identified how a chromosomal abnormality known to be associated with acute lymphoblastic leukemia (ALL)- the most common cancer in children- initiates the disease process. In the July issue of Cell Stem Cell, they describe how expression of this mutation in hematopoietic stem cells (HSCs), which usually occurs before birth, leads to the development of leukemia many years later.
Oncology

DOR BioPharma Receives EMEA Agreement On The Design Of Its Confirmatory Phase 3 Clinical Trial Of OrBec(R) In GI GVHD

further grants and awards, maintain its existing grants which are subject to performance, enter into any biodefense procurement contracts with the US Government or other countries, that the US Congress may not pass any legislation that would provide additional funding for the Project BioShield program, that it will be able to patent, register or protect its technology from challenge and products from competition or maintain or expand its license agreements with its current licensors, or that its business strategy will be successful. Important factors which may affect the future use of orBec(R) for gastrointestinal GVHD include the risks that: the FDA"s requirement that DOR conduct additional clinical trials to demonstrate the safety and efficacy of orBec(R) will take a significant amount of time and money to complete and positive results leading to regulatory approval cannot be assumed; DOR is dependent on the expertise, effort, priorities and contractual obligations of third parties in the clinical trials, manufacturing, marketing, sales and distribution of its products; orBec(R) may not gain market acceptance if it is eventually approved by the FDA; and others may develop technologies or products superior to orBec(R). These and other factors are described from time to time in filings with the Securities and Exchange Commission, including, but not limited to, DOR"s most recent reports on Forms 10-Q and 10-K. Unless required by law, DOR assumes no obligation to update or revise any forward-looking statements as a result of new information or future events. DOR BioPharma, Inc

Pages: 1 [2] 


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009